Predicting coronary heart disease in renal transplant recipients: A prospective study  by Ducloux, Didier et al.
Kidney International, Vol. 66 (2004), pp. 441–447
Predicting coronary heart disease in renal transplant recipients:
A prospective study
DIDIER DUCLOUX, AMIR KAZORY, and JEAN-MARC CHALOPIN
Department of Nephrology and Renal Transplantation, Saint-Jacques Hospital, University of Franche-Comte´, Besanc¸on, France
Predicting coronary heart disease in renal transplant recipients:
A prospective study.
Background. Current cardiovascular risk calculators, widely
used in the general population, have not yet been validated in
renal transplant recipients. We conducted a prospective study to
determine the incidence and risk factors for ischemic heart dis-
ease in renal transplant recipients and to assess the relevance of
the Framingham Heart Study risk calculator in this population.
Methods. Three hundred and forty four consecutive renal
transplant recipients free of vascular disease were enrolled.
Coronary events were registered and analyzed with respect to
traditional and nontraditional cardiovascular risk factors. The
risk of coronary events was assessed through the Framingham
Heart Study formula and the relevance of this equation was
then analyzed.
Results. The patients were followed for a mean duration of
72 ± 14 months. Twenty seven coronary events occurred in
27 patients (7.8%). In addition to risk factors included in the
Framingham Heart Study score, C-reactive protein (CRP) level
(P = 0.009), and hyperhomocysteinemia (P = 0.01) were found
to be independent risk factors for ischemic heart disease events
in renal transplant recipients. The Framingham Heart Study
model did not predict absolute ischemic heart disease risk in
the transplant population as a whole.
Conclusion. Nontraditional cardiovascular risk factors
greatly contribute to increased incidence of ischemic heart dis-
ease events in renal transplant recipients. They should therefore
be considered in preventive care of these patients which relies
on reduction of overall absolute risk. Although the Framingham
Heart Study score has an excellent predictive value in low-risk
renal transplant recipients, it tends to underestimate the real
cardiovascular risk in high-risk patients.
Stable renal transplant recipients have disproportion-
ately high rates of arteriosclerotic disease [1]. An in-
creased prevalence of traditional cardiovascular risk
factors cannot fully explain this increased incidence of
cardiovascular events in this population [2] and recent re-
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ports have emphasized the role of non-traditional cardio-
vascular risk factors, such as hyperhomocysteinemia [3].
Nevertheless, the relative impact of traditional and non-
traditional cardiovascular risk factors on ischemic heart
disease in renal transplant recipients is unknown.
The prevention of coronary heart disease now relies
on the reduction of the overall absolute risk of disease
rather than management of individual risk factors [4].
The strategy for primary prevention is to estimate the
absolute risk of a vascular event and to take appropri-
ate action according to that level of risk [5]. Assessing a
patient’s global risk of cardiovascular disease is consid-
ered as the first step in preventive care, for it enables the
physician to identify and provide the appropriate level
of treatment for risk factors. Some cardiovascular risk
calculators are widely used in the general population.
Nevertheless, there are some controversies about the rel-
evance of these equations such as the Framingham Heart
Study formulae for the transplant population [2]. Despite
their widespread use, these calculators have not yet been
validated in renal transplant recipients [6–8]. Time dis-
crepancies between competitive risk factors, a different
weighting of traditional cardiovascular risk factors in the
renal transplant recipient population and in the general
population, survival bias, and a high prevalence of non-
traditional risk factors in renal transplant recipients may
modify the predictive value of cardiovascular risk calcu-
lator established in the general population.
The purpose of our study was mainly to determine the
risk factors for coronary heart disease in renal transplant
recipients free of vascular disease and then to address
the relevance of the Framingham Heart Study cardiovas-
cular risk calculator in this population.
METHODS
Patients characteristics
Participants in the study were 344 consecutive, stable
French renal transplant recipients with a transplant du-
ration of more than 12 months. The patients were not
included during an episode of acute rejection, or if they
had a serum creatinine level of more than 400 lmol/L.
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Patients with a past history of vascular complications
were excluded in order that the study population cor-
responds to that of the Framingham Heart Study. Never-
theless, we analyzed the incidence of coronary events in
a subgroup of 30 consecutive patients with a past history
of cardiovascular disease in order to provide an indirect
idea of the impact of preexisting cardiovascular disease
on post-transplant outcome.
Two hundred and fifteen patients received antihy-
pertensive drugs (62.5%). Sixty four (29.7%) were on
angiotensin-converting enzyme (ACE) inhibitors and 46
(21.4%) had beta blockers. One hundred and twenty
nine patients (37.5%) received hypolipemiant therapies,
which consisted mostly of statins. A few number of pa-
tients received aspirin (2%).
Immunosuppression therapy consisted of azathioprine
and prednisone alone in 20 patients, while 277 other pa-
tients were treated with similar doses of azathioprine
and prednisone as well as cyclosporine or tacrolimus.
Twenty-three patients were treated with mycophenolate
mofetil and prednisone and 24 patients had similar doses
of mycophenolate mofetil and prednisone as well as cy-
closporine or tacrolimus.
Cardiovascular risk factors
Age, gender, weight, size, blood pressure, hemodialysis
duration before transplantation, diabetes mellitus, smok-
ing status, past history of cardiovascular events, immuno-
suppressive treatment (use of calcineurin inhibitors),
and different biologic parameters were assessed upon
inclusion.
Nutritional status
Albumin concentration was determined and body mass
index (BMI) was calculated [weight/(size)2].
Smoking behavior
Subjects were categorized as current smokers or non-
smokers.
Blood pressure
Blood pressure was measured using a semiautomatic
device, based on an oscillometric method with the pa-
tients in a sitting position after having rested for more
than 5 minutes. Pulse pressure (systolic blood pressure −
diastolic blood pressure) was calculated as well as mean
arterial pressure [diastolic blood pressure + 1/3 (systolic
blood pressure − diastolic blood pressure)].
Left ventricular hypertrophy
Left ventricular hypertrophy (LVH) was defined by a
Sokolow index of greater than or equal to 35.
Lipid profile
Triglycerides, as well as total and high-density lipopro-
tein (HDL) cholesterol serum concentrations were mea-
sured. Low-density lipoprotein (LDL) cholesterol was
calculated using the method described by Friedwald.
Homocysteine
Total plasma homocysteine (tHcy) was measured
using a previously described method [3]. Venous blood
samples were drawn after an overnight fast. The blood
sample was centrifuged for 15 minutes, and plasma
stored frozen at −20◦C. Hcy concentration, the sum
of the acid-soluble (that is, reduced Hcy, homocys-
tine, disulphide, and homocysteine-cysteine–mixed disul-
phide), and protein-bound moieties was measured by
high-performance liquid chromatography (HPLC). This
assay involves the following steps: reduction of the sam-
ple with tri-n-butylphosphine, precipitations of proteins,
alkalinization of the supernatant with sodium borate, de-
rivitization with 7-fluoro-2-oxa-1,3 diazole-4 sulphonate,
followed by 8-aminonaphtalene-1,3,6-trisulphonic acid,
and HPLC separation with fluorescence detection. The
normal values of plasma Hcy concentration ranged from
7 to 15 lmol/L. The precision of the assay corresponds to
a coefficient of variation of less than 3%.
C-reactive protein
C-reactive protein (CRP) was measured by Nephelom-
etry (Kit Beckman, Fullerton, CA, USA).
Renal assessment
Serum creatinine concentration and urinary protein ex-
cretion were measured. Creatinine clearance was calcul-
tated using the Gault-Cockcroft formula.
Parathyroid hormone, vitamin D, calcium, phosphorus
Intact parathyroid hormone (iPTH) was measured us-
ing an immunoradiometric assay, with a normal range of
15 to 80 pg/mL. Vitamin D was measured using kit num-
ber 406095 (Nichols, England), with a normal range of 8
to 52 ng/mL. Calcium and phosphorus were measured by
standard autoanalyzer techniques.
Framingham Heart Study cardiovascular risk calculator
The Framingham Heart Study risk was calculated for
each study subject. For this analysis, we used a Cox anal-
ysis of the Framingham Heart Study population [9].
Coronary heart disease
Coronary heart disease was defined as the follow-
ing clinical events: myocardial infarction documented
Ducloux et al: Predicint coronary heart disease in renal transplant recipients 443
by serial 12-lead electrocardiogram evidence or Q-wave
infarction and appropriate myocardial enzyme eleva-
tions; coronary revascularization, including coronary
artery bypass surgery or percutaneous transluminal coro-
nary angioplasty; or typical history of angina with abnor-
mal coronarography.
Two physicians blinded to the baseline characteristics
of the study patients were responsible for the confirma-
tion of cardiovascular event diagnosis.
Statistical analysis
Arithmetic mean was calculated and expressed as ±
standard deviation (SD).
Using log-rank tests on Kaplan-Meier nonparametric
estimates of the survival without coronary event distri-
bution, we selected variables with a P value lower than,
or equal to, 0.20. The selected variables were included
into a Cox proportional hazards model, and a backward
stepwise selection process was performed, this time at a
classical a = 0.05. The time elapsed since kidney trans-
plantation was bound to vary between patients; therefore,
this duration was forced into the Cox model as a covari-
ate. Gender and age, being potential confounding vari-
ables, were also entered into the Cox model, no matter
the significance of their relationships with cardiovascu-
lar events. The Framingham Heart Study risk (≥20%)
was used as a covariate in the Cox proportional-hazards
model with and without the covariates included in the
Framingham Heart Study risk. Age was split into two
subgroups separated by the median age (49 years) of
the cohort as well as albumin (median = 44 g/L). Serum
Hcy concentrations were split into quartiles (limits 12.9,
16.7, and 20.8 lmol/L) as well as HDL cholesterol (lim-
its 0.45, 0.57, and 0.7 g/L) and CRP (limits 2.1, 3, and
5.2 mg/L). Tobacco consumption was accounted for as
currently smoking versus nonsmoking. Variables that
were split into quartiles were replaced by dummy vari-
ables in the Cox model, which tested quartile 2 versus
quartile 1, quartile 3 versus quartile 1, and quartile 4 ver-
sus quartile 1. Results are expressed as relative risk (RR)
and 95% CI, with a P value testing the null hypothesis:
RR = 1. Therefore, when P value is less than 0.05, RR is
significantly different from 1, either greater than 1 (i.e.,
risk of cardiovascular event is increased) or less than 1
(i.e., risk of cardiovascular event is decreased). Assump-
tions of Cox models (log-linearity, proportionality of risk
in time) were met in this analysis.
RESULTS
The patients were followed for a mean duration of
72 ± 14 months. Their mean age was 51 ± 13.7 years and
217 (63%) were men. Diabetes and LVH were present in
Table 1. Categorical variables in study population
Variable Category Frequency
Gender Male 217 (63%)
Female 127 (37%)
Tobacco consumption Yes 80 (24%)
No 264 (76%)
Diabetes Yes 37 (10.7%)
No 307 (89.3%)
Left ventricle diameter ≥35 mm 25 (7.3%)
<35 mm 319 (92.7%)
Table 2. Continuous variables in study population
Variable Mean SD Median
Age years 51 13 49
Transplant duration months 51 45 48
Creatinine clearance mL/min 54 17 53
Proteinuria g/day 0.42 0.72 0.1
Parathyroid hormone pg/mL 95 145 56
Vitamin D ng/mL 16 13 14
Phosphorus mmol/L 1.17 0.22 1.16
Calcium mmol/L 2.42 0.16 2.44
Hemoglobin g/100 mL 12.8 1.9 13
Fibrinogen g/L 3.91 0.89 3.87
Low-density lipoprotein cholesterol g/L 1.27 0.38 1.24
High-density lipoprotein cholesterol g/L 0.56 0.24 0.55
Total serum cholesterol g/L 2.17 0.48 2.15
Triglycerides g/L 1.57 1.15 1.31
Serum homocysteine mmol/L 18.4 7.01 16.7
Body mass index kg/m2 24.5 4.4 24.1
Systolic blood pressure mm Hg 136 19 140
Diastolic blood pressure mm Hg 81 10 80
Pulse pressure mm Hg 56 15 55
Glycemia mmol/L 5.5 1.3 5.1
C-reactive protein mg/L 4.6 4.2 3.2
Serum albumin g/L 43 4 44
37 patients (10.7%) and 25 (7.3%), respectively. Eighty
patients (24%) were current smokers. Mean time lapse
since transplant and hemodialysis duration were 51 ± 45
and 21 ± 17 months, respectively. Categorical variables
are summarized in Table 1, and continuous variables in
Table 2.
Coronary events
Twenty seven coronary events occurred in 27 patients
(7.8%). Twelve patients (3.4%) died, five (1.5%) of car-
diovascular causes. During the same period of follow-
up, 11 had peripheral vascular complications (3.2%) and
three cerebrovascular disease (1%). By contrast, eight
patients with a past history of cardiovascular disease
(26.7%) experienced a new coronary event during the
same period of follow-up (unadjusted RR 4.11; 95% CI
1.79 to 9.16).
Cardiovascular risk factors
In univariate analysis, age (P < 0.0001), male gender
(P = 0.004), smoking status (P = 0.003), diabetes mellitus
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Table 3. Cox model of cardiovascular risk factors (included or not in
Framingham Heart Study score)
Variable Subgroup RRa 95% CI P value
Framingham <20% 1 — —
Heart Study ≥20% 9.59 [5.05–13.29] <0.0001
score
Age years <51 1 — —
≥51 2.44 [1.47; 7.98] 0.01
C-reactive <2.1 (1st quartile) 1 — —
protein [2.1; 3] (vs. 1st quartile) 1.09 [0.87; 1.42] 0.23
[3; 5.2] (vs. 1st quartile) 1.56 [0.98; 2.67] 0.07
≥5.2 (vs. 1st quartile) 2.65 [1.47; 4.29] 0.009
Serum <12.9 (1st quartile) 1 — —
homocysteine [12.9; 16.7] 2.35 [0.26; 7.03] 0.47b
(vs. 1st quartile)
[16.7; 20.8] 1.28 [0.41; 8.02] 0.32b
(vs. 1st quartile)
≥20.8 (vs. 1st quartile) 4.56 [1.33; 16.68)] 0.01
aAdjusted for time lapse since kidney transplant; bNot significant at a = 5%.
(P = 0.003), low creatinine clearance (P = 0.01), urinary
protein excretion (P = 0.01), high phosphorus concentra-
tion (P = 0.02), high PTH concentration (P = 0.06), high
fibrinogen concentration (P = 0.009), high LDL choles-
terol (P = 0.02), low HDL cholesterol (P < 0.0001), high
tHcy (P = 0.0003), high systolic blood pressure (P = 0.02),
high pulse blood pressure (P = 0.05), glycemia (P = 0.06),
CRP (P < 0.0001), low albumin concentration (P = 0.09)
and high Framingham Heart Study risk (P < 0.0001) were
significantly associated with cardiovascular events.
After backward stepwise selection, the variables which
remained in the Cox proportional hazards model, includ-
ing the Framingham Heart Study risk without covariates
included in its calculation (i.e., linked to cardiovascular
events with P values < 0.05) were found to be Framing-
ham Heart Study risk, serum Hcy, and CRP. Time lapse
since transplantation were kept in the model.
Cox regression analysis revealed that patients in the
higher quartile of tHcy had a significantly greater risk of
cardiovascular events than those in the lowest quartile
(RR 4.56; 95% CI 1.33 to 16.68). Patients in the higher
quartile of CRP had a significantly greater risk of car-
diovascular events than those in the lowest quartile (RR
2.65; 95% CI 1.47 to 4.29) (Table 3). There was a strong
relationship between the Framingham Heart Study cal-
culated risk and cardiovascular events (RR 9.59; 95% CI
5.05 to 13.29).
RRs and their 95% CIs of cardiovascular events for
each variable in the Cox model are displayed in Table 3,
along with P values.
After backward stepwise selection, the variables which
remained in the Cox proportional hazards model with-
out the Framingham Heart Study score (i.e., linked to
cardiovascular events with P values <0.05) were age,
tobacco consumption, diabetes mellitus, low HDL choles-
terol, serum Hcy, and CRP. Gender and time lapse since
transplantation were kept in the model (Table 4).
Framingham Heart Study cardiovascular risk calculator
The study population was divided into low (<20%;
N = 304) and high (≥20%; N = 40) risk patients ac-
cording to the Framingham Heart Study equation. The
mean 10-year risks of the two subgroups were 5.1% and
27.9% respectively. The Framingham Heart Study equa-
tion did not correctly predict the cardiovascular risk of
the whole study population. Indeed, using the Framing-
ham Heart Study calculator, only 16 of the 27 coronary
events had been predictable during the study period. The
overall difference between observed and expected rates
of coronary events was mainly due to the greater inci-
dence of cardiovascular events in high-risk population.
In patients with a low coronary risk (<20% at 10 years),
the predictive value of this calculator was excellent (11
coronary events for 10 expected). By contrast, the Fram-
ingham Heart Study calculator greatly underestimated
coronary events in high-risk patients (16 coronary events
for 7 expected). Most of the nontraditional cardiovascu-
lar risk factors were more prevalent in the Framingham
Heart Study high-risk patients [tHcy (20.7 ± 6 lmol/L
vs. 17.7 ± 5.2 lmol/L; P = 0.01), CRP (6.4 ± 2.1 mg/L vs.
4.2 ± 1.7 mg/L; P = 0.006), fibrinogen (4.5 ± 0.5 g/L vs.
3.1 ± 0.6 g/L; P = 0.001), albumin (42.3 ± 3.1 g/L vs. 44.1 ±
4.3 g/L; P = 0.01), creatinine clearance (43 ± 19 mL/min
vs. 50 ± 17 mL/min; P = 0.01), and urinary protein ex-
cretion (0.7 ± 0.5 g/day vs. 0.41 ± 0.35 g/day; P = 0.03)].
The observed and expected incidences of cardiovascular
events were 0.6% and 0.51% in low-risk patients, and
6.4% and 2.8% in high-risk patients, respectively.
DISCUSSION
There is a high incidence of cardiovascular complica-
tions in the renal transplant population as a whole. In
the present cohort of renal transplant recipients, the cu-
mulative risk for developing ischemic heart disease was
found to be 1.3% within 1 year, which is comparable to
a previous report of our team [3]. Both traditional and
nontraditional cardiovascular risk factors are frequent in
this population and contribute to this increased incidence
of atherosclerotic events. Indeed, we found a strong rela-
tionship between some classic cardiovascular risk factors
included in the Framingham Heart Study score and the
subsequent development of coronary events in the trans-
plant population. Our study also demonstrated that some
so-called nontraditional cardiovascular risk factors also
participates to this increased risk.
The management of renal transplant recipients with
hypertension and/or dyslipidemia is often focused on
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Table 4. Cox model of cardiovascular risk factors not included in the Framingham Heart Study score
Variable Subgroup RRa 95% CI P value
Age <51 years 1 — —
≥51 years 5.32 [1.97; 15.47] 0.005
Tobacco consumption No 1 — —
Yes 2.89 [1.37; 6.78] 0.01
Serum high-density lipoprotein cholesterol <0.45 (1st quartile) 1.56 [1.23; 2.01] 0.03
[0.45; 0.57] (vs. 1st quartile) 1.22 [0.93; 1.42] 0.18
[0.57; 0.7] (vs. 1st quartile) 1.03 [0.78; 1.67] 0.38
≥0.7 (vs. 1st quartile) 1 — —
Diabetes mellitus No 1 — —
Yes 2.31 [1.07; 3.99] 0.02
C-reactive protein <2.1 (1st quartile) 1 — —
[2.1; 3] (vs. 1st quartile) 1.11 [0.77; 1.56] 0.27
[3; 5.2] (vs. 1st quartile) 1.66 [0.96; 2.99] 0.08
≥5.2 (vs. 1st quartile) 2.78 [1.69; 5.11] 0.007
Serum homocysteine mmol/L <12.9 (1st quartile) 1 — —
[12.9; 16.7] (vs. 1st quartile) 2.33 [0.29; 7.13] 0.45b
[16.7; 20.8] (vs. 1st quartile) 1.78 [0.51; 9.092] 0.33b
≥20.8 (vs. 1st quartile) 4.19 [1.62; 17.38)] 0.008
aAdjusted for time lapse since kidney transplant; bnot significant at a = 5%.
therapeutic objectives derived from studies on general
population without adequate regard to their overall car-
diovascular risk. Nevertheless, using absolute risk to
make clinical decision for preventing ischemic heart dis-
ease is no longer questioned. The benefits of treatment
are directly proportional to pretreatment risk [10, 11].
Absolute risk assessment charts are now included in
many guidelines which enable clinicians to rapidly mea-
sure the patient’s absolute risk of coronary heart disease.
However, despite high incidence of ischemic heart dis-
ease in renal transplant recipients, no cardiovascular risk
calculators have yet been validated in this population.
Currently, these calculators, especially those of the Fram-
ingham Heart Study, are widely used to estimate the car-
diovascular risk of renal transplant recipients and predict
the effects of immunosuppressive drugs on this risk [6–
8]. Nevertheless, few studies have reported the predic-
tive value of the Framingham Heart Study equation in
the renal transplant population [2]. Kasiske, Chakkera,
and Roel [2] studied 1124 renal transplant recipients and
observed that the Framingham Heart Study equation pre-
dicts cardiovascular event but tends to underestimate its
real risk. In this study, the underestimation of the real
cardiovascular event risk was likely to be explained by a
change in the weighting of the common risk factors and
to a high prevalence of non-measured risk factors. Our
study is the first to show that the discrepancy between ob-
served and expected incidences of cardiovascular event
is in part due to the high prevalence of some nontra-
ditional risk factors, and their cardiovascular impact in
renal transplant recipients.
Similar to the observation of Kasiske, Chakkera, and
Roel [2], our study revealed that the Framingham Heart
Study equation underestimates the real risk of cardiovas-
cular events in renal transplant recipients. In addition,
our study carries new findings. It shows that Framingham
Heart Study risk calculator accurately predicts cardiovas-
cular events in low-risk renal transplant recipients while
greatly underestimating the true cardiovascular risk of
high-risk patients. Indeed, the higher incidence of car-
diovascular events observed in the transplant population
is almost completely explained by a much higher inci-
dence of cardiovascular events in a small subset of re-
nal transplant recipients cumulating both traditional and
nontraditional cardiovascular risk factors. These findings
have important implications for screening and manage-
ment of patients’ cardiovascular risk and also for future
cardiovascular interventional trials in renal transplant
recipients.
In fact, due to the heterogeneity of the transplant pop-
ulation, a global strategy of cardiovascular prevention is
not warranted and individualization of the risk assess-
ment seems to be mandatory. Using predicted risk for
individual decision-making implies that the prediction is
both accurate and discriminative. Even when the Fram-
ingham Heart Study score does not accurately predict
individual ischemic heart disease risk, it may be used
to identify a high-risk subset of renal transplant recipi-
ents provided that thresholds are defined. General rec-
ommendations are not fully adapted to the diversity of the
transplant population and preventive measures should
focus primarily on the high-risk renal transplant recip-
ients population. In this subset of patients, physicians
should consider both traditional and nontraditional car-
diovascular risk factors in their assessment.
Our study highly suggests that the transplant popula-
tion cannot be considered as a globally homogenous high
cardiovascular risk population. Such a hypothesis may
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overestimate the real risk of the transplant population,
leading to formulate false hypotheses for the design of
interventional studies. For example, a recent study [12]
reported a lower than expected rate of ischemic heart
disease in a selected population of transplant recipients
suggesting that transplant patients do not have a uni-
form increase in cardiovascular risk. This trial failed to
demonstrate a significant impact of statin treatment in
this population, in part due to an overestimation of the
ischemic heart disease risk in this population. Moreover,
an interventional study has been recently stopped be-
cause of a substantial lower rate of cardiovascular events
than expected (SECRET Study). Very high risk patients
(i.e., those with preexisting cardiac disease) are rarely in-
cluded in interventional trials because of study design or
reluctance of investigators to enter patients with complex
therapeutic regimens and severe comorbidity. As a con-
sequence, the observed rate of coronary events is likely
to be lower in such trials than in observational studies,
including the whole transplant population. This may lead
to insufficient power of the study to detect a significant re-
duction in cardiovascular events, appearance of false neg-
ative results, and obtaining erroneous conclusions. Our
study provides relevant informations concerning the real
incidence of ischemic heart disease in renal transplant
recipients with low, mild, and moderate cardiovascular
risk.
Our team and other authors have previously demon-
strated that hyperhomocysteinemia should be considered
one of these risk factors [3, 13, 14]. Elevated plasma con-
centrations of CRP, a sensitive marker of underlying in-
flammation, have been shown to predict an increased risk
of future cardiovascular outcomes in the general popu-
lation [15] as well as in dialysis patients [16–18]. Never-
theless, to our knowledge, our study is the first to address
the deleterious effects of high CRP levels on coronary
heart disease in renal transplant recipients. The mecha-
nisms supporting the association between atherosclerotic
complications and elevated CRP levels remain unclear
[19–21]. Our observation supports the hypothesis that in-
flammation plays a role in the pathogenesis of atheroscle-
rosis in renal transplant recipients.
There are some limitations to our study. The def-
inition of coronary events was not the same as that
used in the Framingham Heart Study. Our definition is
probably more specific but less sensitive and may have
decreased the apparent risk of our population. This dif-
ference may have underestimated the difference between
the Framingham Heart Study–predicted risk and the ob-
served risk in our study population. Moreover, a number
of studies have shown that the Framingham Heart Study
score overestimates coronary heart disease risk in the
French general population [22]. Therefore the accuracy
of the Framingham Heart Study score to predict coronary
events in the low-risk renal transplant recipients is much
likely to reflect the overestimated risk of cardiovascular
events compared to the general French population. The
results of our study should not be generalized to renal
transplant population as a whole. Indeed, patients with a
previous history of cardiovascular disease have not been
included in this study, because such patients do not corre-
spond to the field of application of the Framingham Heart
Study equation. Finally, in our study, hypertension was
not significantly associated with coronary heart disease.
This may be due to relatively short follow-up period or
small sample size of the study population. Alternatively,
effective treatment of blood pressure may decrease the
impact of hypertension on coronary heart disease.
CONCLUSION
Our study demonstrates the cumulative impacts of tra-
ditional and nontraditional cardiovascular risk factors in
renal transplant recipients. The Framingham Heart Study
score may help to select a very high risk population of re-
nal transplant recipients, but does not accurately predict
individual cardiovascular risk except in low-risk patients.
These results have important implications for the assess-
ment of individual cardiovascular risk in renal transplant
recipients and for future interventional studies in this
population.
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